Stock XERS XERIS BIOPHARMA HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Xeris Biopharma Holdings, Inc.

Equities

XERS

US98422E1038

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
1.7 USD -3.41% Intraday chart for Xeris Biopharma Holdings, Inc. -3.41% -27.66%
Mar. 28 Oppenheimer Initiates Coverage on Xeris Biopharma With Outperform Rating, $5 Price Target MT
Mar. 18 Xeris Biopharma Holdings, Inc.(NasdaqGS:XERS) added to S&P Pharmaceuticals Select Industry Index CI

Business Summary

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients’ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.

Number of employees: 377

Sales per Business

USD in Million2022Weight2023Weight Delta
Gvoke, Keveyis and Recorlev
93.6 %
109 99.1 % 153 93.6 % +40.36%
Royalty, Contract and Other
6.4 %
1 0.9 % 11 6.4 % +971.07%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
110 100.0 % 164 100.0 % +48.68%

Managers

Managers TitleAgeSince
Steven Prestrelski FOU
 Founder 60 04-12-31
Paul Edick CEO
 Chief Executive Officer 67 21-10-04
Steven Pieper DFI
 Director of Finance/CFO 47 20-12-31
John Shannon PSD
 President 62 21-10-04
Ken Johnson CTO
 Chief Tech/Sci/R&D Officer 61 21-09-30
Allison Wey IRC
 Investor Relations Contact - -
Kevin McCulloch PRN
 Corporate Officer/Principal - 18-09-30
Beth Hecht LAW
 General Counsel 60 21-09-30

Members of the board

Members of the board TitleAgeSince
John Johnson BRD
 Director/Board Member 66 21-10-04
Jeffrey Sherman BRD
 Director/Board Member 69 21-10-04
Marla Persky BRD
 Director/Board Member 68 21-10-04
Paul Edick CEO
 Chief Executive Officer 67 21-10-04
Garheng Kong BRD
 Director/Board Member 49 21-09-30
John Schmid BRD
 Director/Board Member 60 21-10-04
Barbara-Jean Bormann-Kennedy BRD
 Director/Board Member 65 21-10-04
Dawn Halkuff BRD
 Director/Board Member 53 21-10-04
Ricki Fairley BRD
 Director/Board Member 67 23-03-26

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 148,253,615 142,712,322 ( 96.26 %) 0 96.26 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
6.827 %
9,589,034 6.827 % 21 M $
Vanguard Fiduciary Trust Co.
5.045 %
7,086,345 5.045 % 16 M $
Stonepine Capital Management LLC
4.227 %
5,937,000 4.227 % 13 M $
Caxton Corp.
4.017 %
5,641,920 4.017 % 12 M $
MPM BioImpact, Inc
2.739 %
3,847,232 2.739 % 9 M $
Paul Edick
2.721 %
3,821,494 2.721 % 8 M $
Rosalind Advisors, Inc.
2.523 %
3,543,685 2.523 % 8 M $
Geode Capital Management LLC
2.059 %
2,892,077 2.059 % 6 M $
STATE STREET CORPORATION
1.940 %
2,724,126 1.940 % 6 M $
Steven Pieper
1.158 %
1,626,912 1.158 % 4 M $

Company contact information

Xeris Biopharma Holdings, Inc.

1375 West Fulton Street Suite 1300

60607, Chicago

+

http://www.xerispharma.com
address Xeris Biopharma Holdings, Inc.(XERS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Ratings for Xeris Biopharma Holdings, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.7 USD
Average target price
4.75 USD
Spread / Average Target
+179.41%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
XERIS BIOPHARMA HOLDINGS, INC. Stock Xeris Biopharma Holdings, Inc.
-27.66% 252M
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.37% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.90% 331B
ABBVIE INC. Stock AbbVie Inc.
+7.95% 296B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.00% 233B
NOVARTIS AG Stock Novartis AG
+5.30% 201B
ROCHE HOLDING AG Stock Roche Holding AG
-10.27% 193B
PFIZER, INC. Stock Pfizer, Inc.
-12.26% 143B
AMGEN INC. Stock Amgen Inc.
-6.47% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. XERS Stock
  4. Company Xeris Biopharma Holdings, Inc.